Cargando…

Scleroderma-like Impairment in the Network of Telocytes/CD34(+) Stromal Cells in the Experimental Mouse Model of Bleomycin-Induced Dermal Fibrosis

Considerable evidence accumulated over the past decade supports that telocytes (TCs)/CD34(+) stromal cells represent an exclusive type of interstitial cells identifiable by transmission electron microscopy (TEM) or immunohistochemistry in various organs of the human body, including the skin. By mean...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosa, Irene, Romano, Eloisa, Fioretto, Bianca Saveria, Guasti, Daniele, Ibba-Manneschi, Lidia, Matucci-Cerinic, Marco, Manetti, Mirko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620338/
https://www.ncbi.nlm.nih.gov/pubmed/34830288
http://dx.doi.org/10.3390/ijms222212407
_version_ 1784605196777684992
author Rosa, Irene
Romano, Eloisa
Fioretto, Bianca Saveria
Guasti, Daniele
Ibba-Manneschi, Lidia
Matucci-Cerinic, Marco
Manetti, Mirko
author_facet Rosa, Irene
Romano, Eloisa
Fioretto, Bianca Saveria
Guasti, Daniele
Ibba-Manneschi, Lidia
Matucci-Cerinic, Marco
Manetti, Mirko
author_sort Rosa, Irene
collection PubMed
description Considerable evidence accumulated over the past decade supports that telocytes (TCs)/CD34(+) stromal cells represent an exclusive type of interstitial cells identifiable by transmission electron microscopy (TEM) or immunohistochemistry in various organs of the human body, including the skin. By means of their characteristic cellular extensions (telopodes), dermal TCs are arranged in networks intermingled with a multitude of neighboring cells and, hence, they are thought to contribute to skin homeostasis through both intercellular contacts and releasing extracellular vesicles. In this context, fibrotic skin lesions from patients with systemic sclerosis (SSc, scleroderma) appear to be characterized by a disruption of the dermal network of TCs, which has been ascribed to either cell degenerative processes or possible transformation into profibrotic myofibroblasts. In the present study, we utilized the well-established mouse model of bleomycin-induced scleroderma to gain further insights into the TC alterations found in cutaneous fibrosis. CD34 immunofluorescence revealed a severe impairment in the dermal network of TCs/CD34(+) stromal cells in bleomycin-treated mice. CD31/CD34 double immunofluorescence confirmed that CD31(−)/CD34(+) TC counts were greatly reduced in the skin of bleomycin-treated mice compared with control mice. Ultrastructural signs of TC injury were detected in the skin of bleomycin-treated mice by TEM. The analyses of skin samples from mice treated with bleomycin for different times by either TEM or double immunostaining and immunoblotting for the CD34/α-SMA antigens collectively suggested that, although a few TCs may transition to α-SMA(+) myofibroblasts in the early disease stage, most of these cells rather undergo degeneration, and then are lost. Taken together, our data demonstrate that TC changes in the skin of bleomycin-treated mice mimic very closely those observed in human SSc skin, which makes this experimental model a suitable tool to (i) unravel the pathological mechanisms underlying TC damage and (ii) clarify the possible contribution of the TC loss to the development/progression of dermal fibrosis. In perspective, these findings may have important implications in the field of skin regenerative medicine.
format Online
Article
Text
id pubmed-8620338
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86203382021-11-27 Scleroderma-like Impairment in the Network of Telocytes/CD34(+) Stromal Cells in the Experimental Mouse Model of Bleomycin-Induced Dermal Fibrosis Rosa, Irene Romano, Eloisa Fioretto, Bianca Saveria Guasti, Daniele Ibba-Manneschi, Lidia Matucci-Cerinic, Marco Manetti, Mirko Int J Mol Sci Article Considerable evidence accumulated over the past decade supports that telocytes (TCs)/CD34(+) stromal cells represent an exclusive type of interstitial cells identifiable by transmission electron microscopy (TEM) or immunohistochemistry in various organs of the human body, including the skin. By means of their characteristic cellular extensions (telopodes), dermal TCs are arranged in networks intermingled with a multitude of neighboring cells and, hence, they are thought to contribute to skin homeostasis through both intercellular contacts and releasing extracellular vesicles. In this context, fibrotic skin lesions from patients with systemic sclerosis (SSc, scleroderma) appear to be characterized by a disruption of the dermal network of TCs, which has been ascribed to either cell degenerative processes or possible transformation into profibrotic myofibroblasts. In the present study, we utilized the well-established mouse model of bleomycin-induced scleroderma to gain further insights into the TC alterations found in cutaneous fibrosis. CD34 immunofluorescence revealed a severe impairment in the dermal network of TCs/CD34(+) stromal cells in bleomycin-treated mice. CD31/CD34 double immunofluorescence confirmed that CD31(−)/CD34(+) TC counts were greatly reduced in the skin of bleomycin-treated mice compared with control mice. Ultrastructural signs of TC injury were detected in the skin of bleomycin-treated mice by TEM. The analyses of skin samples from mice treated with bleomycin for different times by either TEM or double immunostaining and immunoblotting for the CD34/α-SMA antigens collectively suggested that, although a few TCs may transition to α-SMA(+) myofibroblasts in the early disease stage, most of these cells rather undergo degeneration, and then are lost. Taken together, our data demonstrate that TC changes in the skin of bleomycin-treated mice mimic very closely those observed in human SSc skin, which makes this experimental model a suitable tool to (i) unravel the pathological mechanisms underlying TC damage and (ii) clarify the possible contribution of the TC loss to the development/progression of dermal fibrosis. In perspective, these findings may have important implications in the field of skin regenerative medicine. MDPI 2021-11-17 /pmc/articles/PMC8620338/ /pubmed/34830288 http://dx.doi.org/10.3390/ijms222212407 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rosa, Irene
Romano, Eloisa
Fioretto, Bianca Saveria
Guasti, Daniele
Ibba-Manneschi, Lidia
Matucci-Cerinic, Marco
Manetti, Mirko
Scleroderma-like Impairment in the Network of Telocytes/CD34(+) Stromal Cells in the Experimental Mouse Model of Bleomycin-Induced Dermal Fibrosis
title Scleroderma-like Impairment in the Network of Telocytes/CD34(+) Stromal Cells in the Experimental Mouse Model of Bleomycin-Induced Dermal Fibrosis
title_full Scleroderma-like Impairment in the Network of Telocytes/CD34(+) Stromal Cells in the Experimental Mouse Model of Bleomycin-Induced Dermal Fibrosis
title_fullStr Scleroderma-like Impairment in the Network of Telocytes/CD34(+) Stromal Cells in the Experimental Mouse Model of Bleomycin-Induced Dermal Fibrosis
title_full_unstemmed Scleroderma-like Impairment in the Network of Telocytes/CD34(+) Stromal Cells in the Experimental Mouse Model of Bleomycin-Induced Dermal Fibrosis
title_short Scleroderma-like Impairment in the Network of Telocytes/CD34(+) Stromal Cells in the Experimental Mouse Model of Bleomycin-Induced Dermal Fibrosis
title_sort scleroderma-like impairment in the network of telocytes/cd34(+) stromal cells in the experimental mouse model of bleomycin-induced dermal fibrosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620338/
https://www.ncbi.nlm.nih.gov/pubmed/34830288
http://dx.doi.org/10.3390/ijms222212407
work_keys_str_mv AT rosairene sclerodermalikeimpairmentinthenetworkoftelocytescd34stromalcellsintheexperimentalmousemodelofbleomycininduceddermalfibrosis
AT romanoeloisa sclerodermalikeimpairmentinthenetworkoftelocytescd34stromalcellsintheexperimentalmousemodelofbleomycininduceddermalfibrosis
AT fiorettobiancasaveria sclerodermalikeimpairmentinthenetworkoftelocytescd34stromalcellsintheexperimentalmousemodelofbleomycininduceddermalfibrosis
AT guastidaniele sclerodermalikeimpairmentinthenetworkoftelocytescd34stromalcellsintheexperimentalmousemodelofbleomycininduceddermalfibrosis
AT ibbamanneschilidia sclerodermalikeimpairmentinthenetworkoftelocytescd34stromalcellsintheexperimentalmousemodelofbleomycininduceddermalfibrosis
AT matuccicerinicmarco sclerodermalikeimpairmentinthenetworkoftelocytescd34stromalcellsintheexperimentalmousemodelofbleomycininduceddermalfibrosis
AT manettimirko sclerodermalikeimpairmentinthenetworkoftelocytescd34stromalcellsintheexperimentalmousemodelofbleomycininduceddermalfibrosis